MX2021015877A - Receptores de celulas t que reconocen la mutacion r175h o y220c en p53. - Google Patents
Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.Info
- Publication number
- MX2021015877A MX2021015877A MX2021015877A MX2021015877A MX2021015877A MX 2021015877 A MX2021015877 A MX 2021015877A MX 2021015877 A MX2021015877 A MX 2021015877A MX 2021015877 A MX2021015877 A MX 2021015877A MX 2021015877 A MX2021015877 A MX 2021015877A
- Authority
- MX
- Mexico
- Prior art keywords
- cell receptors
- mutation
- recognize
- mammal
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4748—Details p53
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867619P | 2019-06-27 | 2019-06-27 | |
| PCT/US2020/039785 WO2020264269A1 (en) | 2019-06-27 | 2020-06-26 | T cell receptors recognizing r175h or y220c mutation in p53 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015877A true MX2021015877A (es) | 2022-04-18 |
Family
ID=71662353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015877A MX2021015877A (es) | 2019-06-27 | 2020-06-26 | Receptores de celulas t que reconocen la mutacion r175h o y220c en p53. |
| MX2026003696A MX2026003696A (es) | 2019-06-27 | 2021-12-16 | Receptores de celulas t que reconocen la mutacion r175h o y220c en p53 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2026003696A MX2026003696A (es) | 2019-06-27 | 2021-12-16 | Receptores de celulas t que reconocen la mutacion r175h o y220c en p53 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12479902B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3990481A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7635165B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220047969A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114341171A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020308004B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021026408A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3144070A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2021015877A (cg-RX-API-DMAC7.html) |
| TW (2) | TW202525841A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020264269A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019077062A1 (en) * | 2017-10-18 | 2019-04-25 | Vivia Biotech, S.L. | C-CELLS ACTIVATED BY BIT |
| JP2024507929A (ja) | 2021-02-25 | 2024-02-21 | アラウノス セラピューティクス インコーポレイテッド | 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 |
| WO2022232599A1 (en) * | 2021-04-30 | 2022-11-03 | Regents Of The University Of Minnesota | Mesothelin-specific t cell receptors and methods of using same |
| AU2022271195A1 (en) * | 2021-05-03 | 2023-11-02 | Bluesphere Bio, Inc. | T cell receptors (tcrs) targeting minor histocompatibility antigen ha-1 |
| EP4334340A1 (en) * | 2021-05-07 | 2024-03-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | T cell receptors recognizing c135y, r175h, or m237i mutation in p53 |
| WO2023060195A1 (en) * | 2021-10-08 | 2023-04-13 | Baylor College Of Medicine | Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy |
| EP4423143A4 (en) * | 2021-10-29 | 2025-10-01 | Yafei Hou | T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| WO2024076692A1 (en) * | 2022-10-05 | 2024-04-11 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as p53 acetylators |
| WO2024163371A1 (en) * | 2023-01-30 | 2024-08-08 | Fred Hutchinson Cancer Center | Binding proteins specific for mutant p53 and uses thereof |
| AU2024241888A1 (en) | 2023-03-27 | 2025-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting y220c or r175h mutation in p53 |
| WO2024220520A2 (en) * | 2023-04-21 | 2024-10-24 | Board Of Regents, The University Of Texas System | T-cell receptors targeting her2 and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| PT3149031T (pt) | 2014-05-29 | 2020-03-25 | Us Health | Receptores de células t anti-e7 do papilomavírus humano 16 |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| IL273515B2 (en) * | 2017-09-29 | 2026-03-01 | Us Health | T cell receptors that recognize mutated P53 |
| JP7391015B2 (ja) * | 2017-09-29 | 2023-12-04 | アメリカ合衆国 | P53がん特異的変異に対して抗原特異性を有するt細胞を単離する方法 |
| CN107748893A (zh) * | 2017-09-29 | 2018-03-02 | 阿里巴巴集团控股有限公司 | 提升车辆定损图像识别结果的方法、装置及服务器 |
| EP4334340A1 (en) | 2021-05-07 | 2024-03-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | T cell receptors recognizing c135y, r175h, or m237i mutation in p53 |
| AU2024241888A1 (en) | 2023-03-27 | 2025-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting y220c or r175h mutation in p53 |
-
2020
- 2020-06-26 WO PCT/US2020/039785 patent/WO2020264269A1/en not_active Ceased
- 2020-06-26 TW TW114110844A patent/TW202525841A/zh unknown
- 2020-06-26 BR BR112021026408A patent/BR112021026408A2/pt unknown
- 2020-06-26 MX MX2021015877A patent/MX2021015877A/es unknown
- 2020-06-26 CN CN202080047882.0A patent/CN114341171A/zh active Pending
- 2020-06-26 US US17/620,942 patent/US12479902B2/en active Active
- 2020-06-26 KR KR1020227002872A patent/KR20220047969A/ko active Pending
- 2020-06-26 CA CA3144070A patent/CA3144070A1/en active Pending
- 2020-06-26 EP EP20742583.6A patent/EP3990481A1/en active Pending
- 2020-06-26 TW TW109121744A patent/TWI908730B/zh active
- 2020-06-26 AU AU2020308004A patent/AU2020308004B2/en active Active
- 2020-06-26 JP JP2021576970A patent/JP7635165B2/ja active Active
-
2021
- 2021-12-16 MX MX2026003696A patent/MX2026003696A/es unknown
-
2025
- 2025-02-12 JP JP2025020882A patent/JP2025081413A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3990481A1 (en) | 2022-05-04 |
| US12479902B2 (en) | 2025-11-25 |
| MX2026003696A (es) | 2026-06-01 |
| BR112021026408A2 (pt) | 2022-02-08 |
| WO2020264269A1 (en) | 2020-12-30 |
| KR20220047969A (ko) | 2022-04-19 |
| TWI908730B (zh) | 2025-12-21 |
| JP2025081413A (ja) | 2025-05-27 |
| TW202525841A (zh) | 2025-07-01 |
| US20220332785A1 (en) | 2022-10-20 |
| AU2020308004A1 (en) | 2022-02-03 |
| AU2020308004B2 (en) | 2026-03-19 |
| TW202108609A (zh) | 2021-03-01 |
| CN114341171A (zh) | 2022-04-12 |
| JP7635165B2 (ja) | 2025-02-25 |
| JP2022538148A (ja) | 2022-08-31 |
| CA3144070A1 (en) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003504A (es) | Receptores de celulas t que reconocen p53 mutado. | |
| BR112021026408A2 (pt) | Receptores de célula t que reconhecem a mutação r175h ou y220c em p53 | |
| MX2024004610A (es) | Receptores de celulas t restringidas a hla de clase ii contra ras mutado. | |
| EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
| SA518391109B1 (ar) | Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ | |
| CY1123385T1 (el) | Υψηλης συγγενειας pd-1 παραγοντες και μεθοδοι χρησης | |
| MX2016015383A (es) | Receptores de celulas t anti - papilomavirus 16 e7 humano. | |
| BR112021022874A2 (pt) | Proteínas de ligação epcam e métodos de uso | |
| EA202092044A1 (ru) | Химерные рецепторы антигена против cd33 и их применения | |
| MX2017006865A (es) | Receptores de células t de kras anti-mutado. | |
| MX2015003061A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida. | |
| BR112022000641A2 (pt) | Modificação genética de célula efetora imune e uso da mesma | |
| MX2017004664A (es) | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. | |
| BR112019007100A2 (pt) | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão | |
| MX2021001158A (es) | Vector hsv oncolitico. | |
| JOP20220079A1 (ar) | بروتين ربط متعددة الخصوصية لمعالجة السرطان | |
| MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
| EA202092093A1 (ru) | Композиции и способы перепрограммирования tcr с применением слитых белков | |
| MX2022009825A (es) | Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v. | |
| CO2022012922A2 (es) | Receptor de células t restringido por hla de la clase i contra ras con mutación g12d | |
| EA201791918A1 (ru) | Модификация белков клеток-хозяев | |
| MX2021002225A (es) | Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion. | |
| AR102595A1 (es) | Anticuerpos anti-ang2 y métodos de utilización | |
| WO2024206274A3 (en) | T cell receptors targeting y220c or r175h mutation in p53 | |
| AR106606A1 (es) | Genes de ataxia de friedreich modificados y vectores para terapia génica |